Xenon Pharmaceuticals (XENE) Reiterated at Overweight by JPMorgan

JPMorgan analyst Tessa Romero reiterated an Overweight rating and $62.00 price target on Xenon Pharmaceuticals (NASDAQ: XENE).

The analyst commented, "We expect to see Xenon’s highly-anticipated topline data in early 2026 ( after The J.P. Morgan Healthcare Conference, to be clear) for the phase 3 X-TOLE2 trial evaluating lead asset, azetukalner, as an adjunctive treatment for patients with focal onset seizures (FOS) . Azetukalner is a novel, potent, small-molecule Kv7 potassium channel opener in late stage development for epilepsy, major depressive disorder, and bipolar depression."

For an analyst ratings summary and ratings history on Xenon Pharmaceuticals click here. For more ratings news on Xenon Pharmaceuticals click here.

Shares of Xenon Pharmaceuticals closed at $41.22 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Bernstein SocGen Group Starts Cipher Mining (CIFR) at Outperform
• Quantinuum raises $1.68 billion in US IPO at $60 per share - Reuters